GERMANY - Gilde portfolio firm signs licensing deal with pharma investor

Munich-based IDEA AG has announced that Celtic Pharmaceutical Holdings LP, an international private equity firm focused on the biotechnology and pharmaceutical industries, has acquiredthrough its subsidiary TDT an exclusive global licence to IDEA’s Transfersome® targeted delivery technology, including global rights to all IDEA’s products in clinical and pre-clinical development except for IDEA’s lead product, IDEA-033, an NSAID indicated against 'deep pain', which IDEA will continue to develop independently.